Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Lenvatinib Phase III Results Show Significant Improvement In Progression-Free Survival In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
Lenvatinib Phase III Results Show Significant Improvement In Progression-Free Survival In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
Lenvatinib Phase III Results Show Significant Improvement In Progression-Free Survival In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
Submitted by
admin
on June 1, 2014 - 11:47am
Source:
Pipeline Review
News Tags:
Lenvatinib
thyroid cancer
Eisai
Headline:
Lenvatinib Phase III Results Show Significant Improvement In Progression-Free Survival In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
Do Not Allow Advertisers to Use My Personal information
